326 related articles for article (PubMed ID: 18245819)
1. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Kourimate S; Le May C; Langhi C; Jarnoux AL; Ouguerram K; Zaïr Y; Nguyen P; Krempf M; Cariou B; Costet P
J Biol Chem; 2008 Apr; 283(15):9666-73. PubMed ID: 18245819
[TBL] [Abstract][Full Text] [Related]
2. In vivo evidence that furin from hepatocytes inactivates PCSK9.
Essalmani R; Susan-Resiga D; Chamberland A; Abifadel M; Creemers JW; Boileau C; Seidah NG; Prat A
J Biol Chem; 2011 Feb; 286(6):4257-63. PubMed ID: 21147780
[TBL] [Abstract][Full Text] [Related]
3. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
Costet P; Cariou B; Lambert G; Lalanne F; Lardeux B; Jarnoux AL; Grefhorst A; Staels B; Krempf M
J Biol Chem; 2006 Mar; 281(10):6211-8. PubMed ID: 16407292
[TBL] [Abstract][Full Text] [Related]
4. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.
Benjannet S; Rhainds D; Hamelin J; Nassoury N; Seidah NG
J Biol Chem; 2006 Oct; 281(41):30561-72. PubMed ID: 16912035
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
6. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
[TBL] [Abstract][Full Text] [Related]
7. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
Davignon J; Dubuc G
Trans Am Clin Climatol Assoc; 2009; 120():163-73. PubMed ID: 19768174
[TBL] [Abstract][Full Text] [Related]
8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
9. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
10. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
Langhi C; Le May C; Kourimate S; Caron S; Staels B; Krempf M; Costet P; Cariou B
FEBS Lett; 2008 Mar; 582(6):949-55. PubMed ID: 18298956
[TBL] [Abstract][Full Text] [Related]
11. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
13. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Dubuc G; Chamberland A; Wassef H; Davignon J; Seidah NG; Bernier L; Prat A
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1454-9. PubMed ID: 15178557
[TBL] [Abstract][Full Text] [Related]
14. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
Dong B; Wu M; Cao A; Li H; Liu J
Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Awan Z; Baass A; Genest J
Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
Maxwell KN; Breslow JL
Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
[TBL] [Abstract][Full Text] [Related]
18. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
20. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.
Mayne J; Dewpura T; Raymond A; Cousins M; Chaplin A; Lahey KA; Lahaye SA; Mbikay M; Ooi TC; Chrétien M
Lipids Health Dis; 2008 Jun; 7():22. PubMed ID: 18547436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
